Danisco A/S v Novozymes A/S (No 2)

Link copied
Case Copied 80 min read

FEDERAL COURT OF AUSTRALIA

Danisco A/S v Novozymes A/S (No 2) [2011] FCA 282

Citation: Danisco A/S v Novozymes A/S (No 2) [2011] FCA 282
Parties: DANISCO A/S and DANISCO AUSTRALIA PTY LTD (ACN 096 139 392)   v NOVOZYMES A/S and NOVOZYMES AUSTRALIA PTY LTD 
(ACN 001 420 677)
File number: NSD 1968 of 2008
Judge: BENNETT J
Date of judgment: 29 March 2011
Catchwords:

PATENTS – construction of claims – clarity – claim narrower than specification – meaning of “an enzyme” – meaning of “generated from” – meaning of “functional ingredient” – meaning of “inactivating or denaturing the enzyme” – construction difficult – not render claim invalid – clear construction available

PATENTS – construction of claims – based on language of independent claim, second constituent does not include water – water stated as a second constituent in specification and dependent claim – patentee says reference to water is a “mistake” – whether water can be constituent of independent claim

PATENTS – construction of claims – limitation by result – inactivated or denatured enzyme – standard of inactivation – workable standard – no significant or material amount of active enzyme

PATENTS – invention – relevance of Invention Disclosure Statement to construction of claims – relevance of Invention Disclosure Statement to inventive step – relevance of Invention Disclosure Statement to characterisation of invention

PATENTS – infringement – whether infringement by supply of product pursuant to Patents Act 1990 (Cth) s 117 – ss 117(2)(a), (b) and (c) – whether indirect infringement as joint tortfeasor

PATENTS – validity – novelty – understanding of skilled reader following directions in prior publication – whether following directions would disclose the process – whether following directions would disclose the results of the process being essential integers of the claims – whether there was disclosure of products of the process as functional ingredients – whether information in prior publication discloses the integers of the claimed process

PATENTS – validity – novelty – anticipation by use –
whether anticipation by “inevitable result” – inherent activity of enzyme disclosed – whether clear and unmistakable directions to the process of the claims where claims include specified result and meaning of prior information – whether, where disclosure is incomplete in prior publication, completion by following directions must be publicly available prior to priority date – whether anticipation by “inevitable result” where resulting information not available prior to priority date – enzyme and clone deposited – hypothetical use – whether enzyme could in fact have been obtained for use prior to priority date – whether information equating to the result was disclosed prior to the priority date – whether skilled addressee would know that result of use of enzyme in prior art document was claimed process – whether necessary for anticipation by inevitable result for directions in prior art document to have been able to be followed by skilled addressee before priority date of the patent

PATENTS – validity – novelty – “whole of contents” citation pursuant to paragraph (b)(ii) of “prior…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Danisco A/S v Novozymes A/S (No 2) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2011] FCA 282
Decision Date

CaseChat Overview and Summary

In the case of Danisco A/S v Novozymes A/S (No 2), the primary dispute revolves around the interpretation, validity, and infringement of certain patent claims held by Danisco A/S. The Federal Court of Australia was tasked with resolving various issues pertaining to the clarity, scope, and novelty of the patent claims as well as determining whether Novozymes A/S had infringed these claims.

The legal issues addressed by the court included the construction of specific terms within the patent claims, the necessity of clarity in patent claims, the criteria for novelty and inventive step, and the conditions under which infringement occurs. Notably, the court had to interpret phrases such as "an enzyme," "generated from," "functional ingredient," and "inactivating or denaturing the enzyme" in the context of the patent claims. The court also examined whether certain elements, such as water, could be considered constituents of the independent claim despite not being explicitly mentioned. Furthermore, the court considered whether the claims were sufficiently clear and whether the patent was valid under Australian law, specifically addressing the grounds of lack of manner of manufacture, lack of novelty, and lack of inventive step.

The court’s reasoning centred on the principle that patent claims must be interpreted based on their language, while also considering the specification and prior art. The court found that a clear construction of the claims was possible and did not render them invalid. It concluded that the claims were sufficiently clear and did not suffer from lack of clarity, lack of manner of manufacture, lack of novelty, or lack of inventive step. The court also determined that Novozymes A/S had infringed the patent claims by supplying a product in a manner that fell within the scope of the patent, as defined by section 117 of the Patents Act 1990 (Cth). The court found that the claims were valid and that Novozymes’ cross-claim should be dismissed.

The final orders of the court required the parties to submit draft orders for the court's approval, to notify the court of any confidentiality concerns, and to stand the matter over for further directions. The court's decision was pivotal in affirming the validity of the patent claims and establishing that Novozymes A/S had indeed infringed these claims.

Orders

Orders of the court

1. The parties submit draft orders to give effect to these reasons, including as to reserved costs and the future conduct of the proceedings, by 4 p.m. on 31 March 2011.

2. The parties notify Bennett J’s chambers by 4 p.m. on 30 March 2011 if there are confidentiality concerns as to [141] and [163] of the reasons.

3. The matter be stood over for directions to 9:30 a.m. on 1 April 2011.

Note:

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Novozymes does not rely on any other reference for this ground of alleged invalidity. There is no admission in the specification, nor is it apparent on the face of the specification, that there is no invention or no sufficient inventiveness described or claimed. Revocation on the ground of lack of manner of manufacture is not made out.CONCLUSION Claims 1 to 9 and 14 to 15 of the Patent are not invalid on the bases of lack of manner of manufacture, lack of novelty or lack of an inventive step. The claims of the Patent are not invalid for want of clarity. Novozymes’ cross-claim should be dismissed. Novozymes has infringed claims 7 and 14 of the Patent pursuant to s 117(1) of the Act and as a joint tortfeasor.

Ratio Decidendi

Legal Principle Established

Novozymes submits that Danisco’s construction ignores the specification which, it says, does not specifically describe or exemplify the use of a single conversion agent to catalyse the hydrolysis of two different fatty acid esters. Novozymes contends that it is unlikely that the specification is silent about the very thing which Danisco submits is the invention. Novozymes points out that, on Danisco’s construction, the claim is limited to hydrolysis reactions which must involve two different types of fatty acid esters and that claim 1 excludes transesterification reactions. This, Novozymes says, supports its construction of claim 1 as a single reaction whereby the enzyme catalyses the reaction or interaction between the fatty acid ester and the second constituent. Danisco’s construction, Novozymes says, is one advanced ‘with an eye to the allegedly infringing article’ and with ‘an eye to the prior art’, which is impermissible.Consideration Professor Small and Professor Hoseney agreed that the one enzyme/two reactions scheme is within the claims, where an emulsifier and a second functional ingredient are generated from their respective constituents by a single enzyme by way of two hydrolysis reactions. That is, claim 1 is not limited to the use of an enzyme in a single reaction. Each expert agrees that if there were two reactions whereby the enzyme acted on two separate substrates, in each case another reactant would be necessary to produce, for example, the emulsifier. This could, according to Professor Small, be water, glycerol or ‘a number of possibilities’. Novozymes contends that if there are two reactions, the second reactants in each case are not identified. There is no evidence that the skilled reader such as Professor Hoseney or Professor Small, in carrying out a reaction whereby an enzyme acted on a fatty acid ester to produce an emulsifier, would have difficulty in determining what separate reactant would be necessary or useful to achieve that outcome. For example, it could be said that in a hydrolysis reaction, water as a second reactant is “a given”. The evidence is silent as to the skilled reader’s understanding from the specification as to how to achieve the two reactions Danisco contends for. This may be because neither fair basis nor lack of sufficient description under s 40 of the Act are pleaded grounds of invalidity. There is no basis on which to contend that the skilled reader would have difficulty in working the claimed process as a one enzyme/two reactions scheme. The skilled reader does not need the second reactants to be identified. The next question is whether the one enzyme/one reaction scheme is also included in claim 1. The assumption that the unspecified reactants of a “dual reaction” scheme are water for a hydrolysis reaction or glycerol for a glycerolysis reaction does not provide a complete answer to Novozymes’ submission that the claim also describes a single reaction, because the claim is not limited, for example, to hydrolysis reactions. I accept that, in addition to describing two reactions catalysed by the one enzyme, claim 1 may also, as a matter of grammatical construction, describe a single reaction in which the enzyme acts on the fatty acid ester to generate the first functional ingredient. In the same reaction, a second functional ingredient is generated from the second constituent. This would depend on the nature of the second constituent. In one way, the second functional ingredient could be seen as a by-product of the action of the enzyme on the first constituent.What is the meaning of “generated from”?